◉  First Press Release 

◉  Second Press Release

◉  Fourth Discretionary Advisory  Committee on Heritable Diseases in Newborns and Children, DACHDNC

◉  Public meeting on Patient-Focused Drug Development for Neurological Manifestations of Inborn Errors of Metabolism

◉  FDA, Division of Gastroenterology & Inborn Error Products, meeting, September 29, 2014

◉  The FDA approved the use of cholic acid for peroxisomal disorders today, 3/17/15 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm438572.htm

◉  Pilot Study of DHA-EE

◉  Awake Not the Hungry  Published!

◉  Congratulations to Alex and Ana Paula for graduating from Middle School (See Families Page, Ana Paula and Alex Case History). 

• ◉  At Bio 2022, Biotechnology International Convention, Travere Therapeutics is sponsoring videos featuring people living with different types of conditions, including rare diseases, with the goal to elevate the voices of patients, families, and patient advocacy organizations.  Matthew’s story is included.  https://travere.com/rare-life/matthew/